<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04856982</url>
  </required_header>
  <id_info>
    <org_study_id>233AS303</org_study_id>
    <secondary_id>2020-004590-51</secondary_id>
    <nct_id>NCT04856982</nct_id>
  </id_info>
  <brief_title>A Study of BIIB067 When Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation</brief_title>
  <acronym>ATLAS</acronym>
  <official_title>A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of BIIB067 when initiated in&#xD;
      presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated&#xD;
      neurofilament (NF). The secondary objectives of this study are to evaluate the safety and&#xD;
      tolerability of BIIB067 and to evaluate the effect of BIIB067 on pharmacodynamics&#xD;
      (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of&#xD;
      clinically manifest amyotrophic lateral sclerosis (ALS).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 17, 2021</start_date>
  <completion_date type="Anticipated">August 7, 2027</completion_date>
  <primary_completion_date type="Anticipated">August 7, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Parts B and C: Percentage of Participants with Emergence of Clinically Manifest ALS Within 12 Months of Part B Baseline</measure>
    <time_frame>Up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Percentage of Participants with Emergence of Clinically Manifest ALS Within 24 Months of Part B Baseline</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Time to Emergence of Clinically Manifest ALS</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Change in ALS Functional Rating Scale (ALSFRS-R) Total Score</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>The ALSFRS-R measures 4 functional domains: respiratory, bulbar function, gross motor skills, and fine motor skills. There are 12 questions, each scored from 0 to 4, for a total possible score of 48, with higher scores representing better function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Change from Baseline in Percent Predicted Slow Vital Capacity (SVC)</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Percentage of Participants with Outcome as Death or Permanent Ventilation Based on Time to Death or Permanent Ventilation Analysis</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Permanent ventilation is defined as ≥22 hours of invasive or noninvasive mechanical ventilation per day for ≥21 consecutive days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B and C: Percentage of Participants with Outcome as Deaths Based on Time to Death Analysis</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B, C and D: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) during the Treatment Period</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B, C and D: Change from Baseline in Plasma NfL Concentrations</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Parts B, C and D: Change in Total Cerebrospinal Fluid (CSF) SOD1 Concentrations</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation</condition>
  <arm_group>
    <arm_group_label>Part A: Natural History Run-in</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants enrolled in Part A will undergo blood draws approximately once every 28 days to assess neurofilament light chain (NfL) levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Randomized, Double-Blind, Placebo-Controlled</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Part A who meet the protocol-defined NfL threshold and remain presymptomatic may be eligible to participate in Part B. During Part B, participants will receive BIIB067 100 milligram (mg) or placebo via intrathecal (IT) injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Open-Label Extension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Part B who develop clinically manifest ALS may be eligible to participate in Part C. During Part C, participants who received placebo in Part B will receive BIIB067 100 mg via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years. Participants who received BIIB067 during Part B will receive BIIB067 100 mg on Days 1, 29, and every 28 days thereafter for up to 2 years, with a dose of placebo on Day 15 to maintain the study blind.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: Randomized, Double-Blind, Placebo-Controlled</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Part A who develop clinically manifest ALS prior to randomization in Part B may be eligible to participate in Part D. During Part D, participants will be randomized to receive BIIB067 100 mg or placebo via IT injection on Days 1, 15, 29, and every 28 days thereafter for up to 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB067 (Tofersen)</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>Part B: Randomized, Double-Blind, Placebo-Controlled</arm_group_label>
    <arm_group_label>Part C: Open-Label Extension</arm_group_label>
    <arm_group_label>Part D: Randomized, Double-Blind, Placebo-Controlled</arm_group_label>
    <other_name>Tofersen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as specified in the treatment arm</description>
    <arm_group_label>Part B: Randomized, Double-Blind, Placebo-Controlled</arm_group_label>
    <arm_group_label>Part C: Open-Label Extension</arm_group_label>
    <arm_group_label>Part D: Randomized, Double-Blind, Placebo-Controlled</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Part A Inclusion Criteria:&#xD;
&#xD;
          -  Participants should have a protocol-defined rapidly progressive SOD1 mutation,&#xD;
             confirmed by a central reader, or a SOD1 mutation that is approved for inclusion by an&#xD;
             external mutation adjudication committee.&#xD;
&#xD;
          -  Participants with plasma NfL level less than the protocol-defined threshold.&#xD;
&#xD;
          -  Participants who are clinically presymptomatic for ALS (i.e., must not have clinically&#xD;
             manifest ALS).&#xD;
&#xD;
        Key Part A Exclusion Criteria:&#xD;
&#xD;
          -  History or positive test result at screening for human immunodeficiency virus (HIV).&#xD;
             The requirement for testing at Screening may be omitted if it is not permitted by&#xD;
             local regulations.&#xD;
&#xD;
          -  Current hepatitis C infection (defined as positive Hepatitis C Virus (HCV) antibody&#xD;
             and detectable HCV RNA). Participants with positive HCV antibody and undetectable HCV&#xD;
             Ribonucleic Acid (RNA) are eligible to participate in the study (United States Centers&#xD;
             for Disease Control and Prevention).&#xD;
&#xD;
          -  Current hepatitis B infection (defined as positive for hepatitis B surface antigen&#xD;
             (HBsAg) and/or anti-Hepatitis B Core antibody (HBc)). Participants with immunity to&#xD;
             hepatitis B from previous natural infection (defined as negative HBsAg, positive&#xD;
             anti-HBc, and positive anti-hepatitis B surface antibody (HBs) or vaccination (defined&#xD;
             as negative HBsAg, negative anti-HBc, and positive anti- HBs) are eligible to&#xD;
             participate in the study.&#xD;
&#xD;
          -  History of systemic hypersensitivity reaction to tofersen, the excipients contained in&#xD;
             the formulation, and if appropriate, any diagnostic agents to be administered during&#xD;
             the study.&#xD;
&#xD;
          -  History of confounding neuromuscular or neurological disorder that is expected to have&#xD;
             a progressive (i.e., worsening) course during the study, and/or is expected to be&#xD;
             associated with elevations in NF, in the opinion of the Investigator.&#xD;
&#xD;
          -  Presence of risk for increased or uncontrolled bleeding and/or risk of bleeding that&#xD;
             if not managed optimally could place a participant at an increased risk for&#xD;
             intraoperative or postoperative bleeding.&#xD;
&#xD;
          -  Significant cognitive impairment, clinical dementia, or unstable psychiatric illness,&#xD;
             including psychosis, suicidal ideation, suicide attempt, or untreated major depression&#xD;
&#xD;
             ≤ 90 days of screening, which in the opinion of the Investigator would interfere with&#xD;
             the study procedures.&#xD;
&#xD;
          -  Treatment with riluzole and/or edaravone. If the participant has been on riluzole&#xD;
             and/or edaravone, the medication(s) must be discontinued for at least 5 half-lives&#xD;
             prior to screening.&#xD;
&#xD;
          -  Use of off-label treatments for ALS.&#xD;
&#xD;
          -  Treatment with another investigational drug (including investigational drugs for ALS&#xD;
             through compassionate use programs), biological agent, or device within 1 month or 5&#xD;
             half-lives of study agent, whichever is longer. Specifically, no prior treatment with&#xD;
             small interfering RNA, stem cell therapy, or gene therapy is allowed.&#xD;
&#xD;
          -  Anticipated need, in the opinion of the Investigator, for administration of any&#xD;
             antiplatelet or anticoagulant medication (e.g., clopidogrel) that cannot be safely&#xD;
             continued or held for an LP procedure, if necessary, according to local or&#xD;
             institutional guidelines and/or Investigator determination.&#xD;
&#xD;
          -  Current enrollment or a plan to enroll in any interventional clinical study in which&#xD;
             an investigational treatment, biological agent, device, or approved therapy for&#xD;
             investigational use. Participation in a noninterventional study focused on ALS natural&#xD;
             history may be allowed at the discretion of the Investigator.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria will apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Biogen Clinical Trial Center</last_name>
    <phone>866-633-4636</phone>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Global Biogen Clinical Trial Center</last_name>
    <email>clinicaltrials@biogen.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Razavi</last_name>
      <phone>415-600-0486</phone>
      <email>razavirf@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jonathan Katz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital Phil Smith Neuroscience Institute</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donovan Mott</last_name>
      <phone>954-542-3442</phone>
      <email>donovan.mott@holy-cross.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Locatelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Laure Grignon</last_name>
      <email>axg1571@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Benatar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meraida Polak</last_name>
      <phone>404-778-3807</phone>
      <email>mpolak@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathan Glass</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Robert Bucelli</last_name>
      <phone>844-257-2273</phone>
      <email>als@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Neuromuscular Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yessar Hussain</last_name>
      <email>yessar@austinneuromuscle.com</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Gonsoulin</last_name>
      <email>stephanie@austinneuromuscle.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2109</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04037-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaelle Bruneteau</last_name>
      <email>maryvonne.retail@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima-Ken</state>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Tokyo Hospital</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo-To</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>4763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Neuro Protect</name>
      <address>
        <city>Warszawa</city>
        <zip>01-684</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maciej Czarnecki</last_name>
      <phone>+48 501762789</phone>
      <email>maciej.czarnecki@neuroprotect.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital of Umea</name>
      <address>
        <city>Umeå</city>
        <zip>90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Andersen</last_name>
      <email>peter.andersen@umu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sheffield</city>
        <state>Staffordshire</state>
        <zip>S10 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.alsATLASstudy.com</url>
    <description>Disclaimer: Residents in the United States may click here to find out more about participation in this trial.</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on http://clinicalresearch.biogen.com/</ipd_description>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

